1387373
Last Update Posted: 2020-10-05
Recruiting has ended
All Genders accepted | 18 Years + |
14 Estimated Participants | No Expanded Access |
Interventional Study | Does not accept healthy volunteers |
Intra-hepatic Chemotherapy in Patient With Non-resectable Liver Metastases From Breast Cancer
This is a phase II trial evaluating intra-hepatic chemotherapy with oxaliplatin every second week in combination with systemic capecitabine and in patients with a HER2-positive tumour in combination with trastuzumab (Herceptin®) in patient with non-resectable liver metastases from breast cancer.
Only patients without extrahepatic disease are included.
Eligibility
Relevant conditions:
Metastatic Breast Cancer
Liver Metastases
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the study if you think are close to fitting criteria.
locations
Data sourced from ClinicalTrials.gov